In China, the ophthalmology market is expected to grow from USD 1.8 billion in 2015 to USD 20.2 billion by 2030 ... a 17.5 percent increase…
In Conversation
Current methods [of cancer testing] often detect cancer at later stages through protein markers. Our aim is to revolutionize this by introducing early cancer detection, starting…
In just five years we have built an Asian hub for international biotechnology listings in Hong Kong
I feel that the region is ready to bring in [gene] therapies, both in terms of regulatory affairs as well as pricing schemes
With the amount of data available through Hong Kong's Hospital Authority database, precision and personalised medicine could be a good focus for the city
The business model offered by NewBridge is becoming more relevant and a mainstay in the industry across emerging markets, not just MENA
I believe it is our responsibility as the market leaders in Hong Kong to shape the ecosystem
There are over 100 VC funds in Southern China, so there is plenty of opportunity for these young companies, and we have participated in co-funding
Thanks to generative AI we can double Big Pharma’s R&D productivity in a very small biotech setting
Competition [between pharma companies in MENA] is only getting more intense due to the increasing demand and decreasing cost of manufacturing
It is important that if a patient is diagnosed, the treatment is always readily available, so we are working with the relevant stakeholders, such as payers,…
Having built my experience in the US, I learnt that it does not matter who you are, you must always be learning and be an expert…
